Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Vivek S. Kavadi, MD

Latest:

Maintaining the Pace of Progress

Over the past 40 years, since the declaration of the War on Cancer in 1971, we have seen tremendous advances in our struggle with this deadly disease.

Vivek Subbiah, MD, MD Anderson Cancer Center

Latest:

Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Vivek Venkatramani, MD

Latest:

Landmark Trial Puts Robotic Surgery to the Test in Bladder Cancer

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Vivek Verma, MD

Latest:

Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical Implications

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.

Vivianne Tjan-Heijnen, MD, PhD

Latest:

Dr. Tjan-Heijnen on Results of DATA Study in Breast Cancer

Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Vladimir Yankov, MD

Latest:

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Volker Diehl, MD

Latest:

Dr. Diehl Discusses Brentuximab Vedotin

Dr. Volker Diehl from the University of Cologne Discusses Brentuximab Vedotin

Volker Heinemann, MD, PhD

Latest:

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Volker Heinemann, MD, University of Munich

W. Kimryn Rathmell, MD, PhD

Latest:

Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus

Renal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).

W. Marston Linehan, MD

Latest:

Dr. Linehan on Treatment for Hereditary Leiomyomatosis and RCC

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses the treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC).